Maze Therapeutics Inc MAZE
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2025-01-31 |
| Shares Out. | 55,350,000 |
| Website | mazetx.com/ ↗ |
| Phone | 16508505070 |
| Employees | 141 |
| Revenue | $20.0M |
| Gross Profit | $20.0M |
| Net Income | -$24.2M |
| Free Cash Flow | -$122.1M |
| Total Assets | $419.7M |
| Total Liabilities | $78.0M |
| Equity | $341.7M |
About Maze Therapeutics Inc
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Maze Therapeutics Inc is a publicly traded company under the ticker symbol MAZE on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)